Kamal Saini, Executive Medical Director, Head of European Oncology Team at Fortrea, shared a post on LinkedIn:
” ‘Transformers to Transform Medicine?’
Intriguing question posed at the ESMO – European Society for Medical Oncology AI and Digital Oncology conference (ESMOAI25 Berlin, Nov 12-14, 2025).
Interestingly, Fortrea medic Luca Cantini recently co-authored two manuscripts on transformer-based AI approaches in lung cancer:
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. J Immunother Cancer. 2025 Sep 29;13
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer. 2025 Oct 16:209:108799.
Fortrea medical oncologists Amanda Nogueira, María García Requesens, and I are attending this interesting and important conference and are happy to connect and discuss! AI is becoming integral to cancer clinical trials!”
More posts featuring Kamal Saini.